Monk, Bradley J <br/><br/>
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Oct 2012 
 - 2361-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2012.04.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Ovarian Epithelial<br/>Dioxoles--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Polyethylene Glycols--administration & dosage<br/>Survival Analysis<br/>Tetrahydroisoquinolines--administration & dosage<br/>Trabectedin